#United States #Washington #ARPA-H #Global Genes #RARE-X

Global Genes Partners with Leading Institutions for Rare Disease Innovation

In a significant development for the rare disease community, Global Genes, a preeminent nonprofit organization dedicated to advocating for patients with rare diseases, has announced its involvement in a groundbreaking consortium. This collaborative effort has been awarded up to $35 million from the Advanced Research Projects Agency for Health (ARPA-H), specifically for its Rare Disease AI/ML for Precision Integrated Diagnostics (RAPID) program. The consortium is spearheaded by the University of North Carolina School of Medicine and Emory University, with the ambitious goal of establishing a unique data repository that will utilize artificial intelligence to uncover critical insights aimed at enhancing diagnostic accuracy and treatment discovery.

The Importance of Addressing Rare Diseases

Rare diseases affect millions of people globally, with estimates indicating around 350 million individuals suffer from over 10,000 different conditions. Notably, one in every ten Americans is impacted by a rare disease. Unfortunately, the journey to a proper diagnosis can be lengthy and arduous. Statistics indicate that patients often endure a diagnostic odyssey, requiring more than six years and nearly 17 healthcare visits before obtaining an accurate diagnosis. This delay not only amplifies the emotional toll on patients and families but also leads to substantial unnecessary medical expenses, which can range from $86,000 to $517,000 for each patient.

Recognizing these dire challenges, the RAPID program seeks to bridge the existing gap in rare disease diagnosis by harnessing large-scale data and cutting-edge AI technology. The vision is to enable earlier and more precise identification of rare diseases, thereby expediting patient access to essential care and treatment options.

Global Genes' Unique Contributions to the Initiative

Global Genes is bringing significant expertise and resources to the RAPID initiative. The organization is notable for its extensive experience in fostering community advocacy within the rare disease space. By leveraging this knowledge, Global Genes aims to enhance patient engagement and trust among affected communities.

In addition, the organization will utilize its RARE-X Research Program, which features a patient-driven data platform that has garnered participation from over 10,000 individuals with rare diseases. This unique platform enables patients and their families to voluntarily share their health information to expedite research initiatives. With data sourced from nearly 100 diseases and collaboration with over 130 advocacy groups, RARE-X stands as one of the most comprehensive datasets focused on rare diseases, actively nurturing engaged communities.

As part of the RAPID program, current and future RARE-X contributors will have the opportunity to consent to have their data included in the project, emphasizing Global Genes' commitment to patient choice and informed consent. Stringent privacy measures will be implemented to safeguard patient data, including anonymizing personal identifiers before submission to the RAPID database.

A Comprehensive Dataset with Broad Implications

The consortium's approach includes aggregating diverse data from various partners, including academic institutions, for-profit entities, and nonprofit organizations. This will encompass health records, medical imaging, insurance claims, patient surveys, and even video technologies. The combination of these rich data sources will equip healthcare providers and researchers with the tools necessary to uncover the mechanisms of rare disease progression, identify diagnostic patterns beyond specialized medical facilities, and enhance clinical trial design, ultimately driving faster advancements in drug development.

Global Genes’ CEO, Charlene Son Rigby, expressed her enthusiasm about the initiative, stating, "Every rare disease patient deserves an answer. The RAPID initiative gives us a genuine opportunity to change how rare diseases are diagnosed and treated. We are grateful to ARPA-H, UNC, Emory, and our consortium partners for their commitment to the rare disease community."

About Global Genes and RARE-X

For nearly twenty years, Global Genes, a 501(c)(3) non-profit organization, has been pivotal in alleviating the many burdens faced by rare disease patients and their families worldwide. The organization empowers advocates with essential resources, training, and support to connect individuals with necessary care and to facilitate research endeavors. Supporting over 400 million individuals affected by rare diseases, Global Genes collaborates with industry partners and academic institutions to foster a thriving ecosystem essential for the advancement of rare disease research.

RARE-X stands as Global Genes' research initiative, offering an innovative, scalable model for the collection of rare disease data in collaboration with advocacy groups. The project's global reach encompasses over 95 disorders represented by patients from 90 countries, contributing to robust data aimed at accelerating research and propelling urgently needed treatments forward.

For those interested in learning more about this vital initiative, further information about Global Genes and the RARE-X program can be found at their official website.